LOGIN  |  REGISTER
Recursion
Compass Therapeutics

Penumbra to Present at Upcoming Investor Conferences

May 20, 2025 | Last Trade: US$266.75 3.64 -1.35

ALAMEDA, Calif., May 20, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the following investor conferences on the dates and times listed below.

Event:

William Blair 45th Annual Growth Stock Conference

Date:

Tuesday, June 3, 2025

Time:

3:00pm ET/12:00pm PT

Event:

Jefferies Global Healthcare Conference

Date:

Wednesday, June 4, 2025

Time:

9:55am ET/6:55am PT

Event:

Truist Securities MedTech Conference

Date:

Tuesday, June 17, 2025

Time:

10:00am ET/7:00am PT

Webcasts of the presentations can be accessed on the "Events and Presentations" section under the "Investors" tab of the company's website at www.penumbrainc.com. The webcasts will be available on the company's website for at least two weeks following each event.

About Penumbra 

Penumbra, Inc., the world's leading thrombectomy company, is focused on developing the most innovative technologies for challenging medical conditions such as ischemic stroke, venous thromboembolism such as pulmonary embolism, and acute limb ischemia. Our broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe with speed, safety and simplicity. By pioneering these innovations, we support healthcare providers, hospitals and clinics in more than 100 countries, working to improve patient outcomes and quality of life. For more information, visit www.penumbrainc.com and connect on Instagram, LinkedIn and X.

Investor Relations

Penumbra, Inc.

This email address is being protected from spambots. You need JavaScript enabled to view it.

Viking Therapeutics

Stock Quote

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page